Valuation: AtaiBeckley Inc.

Capitalization 1.35B 1.15B 1.07B 1.01B 1.87B 125B 1.91B 12.59B 4.91B 60.15B 5.06B 4.96B 215B P/E ratio 2026 *
-7.63x
P/E ratio 2027 * -7.78x
Enterprise value 1.18B 1.01B 930M 877M 1.63B 109B 1.66B 10.98B 4.28B 52.44B 4.42B 4.32B 187B EV / Sales 2026 *
2,732x
EV / Sales 2027 * 8,799x
Free-Float
90.01%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: AtaiBeckley Inc.

1 day+0.54%
1 week-2.37%
Current month+4.52%
1 month-4.88%
3 months-1.33%
6 months-32.11%
Current year-9.54%
1 week 3.65
Extreme 3.65
3.97
1 month 3.26
Extreme 3.265
4.15
Current year 3.26
Extreme 3.265
4.4
1 year 1.19
Extreme 1.1927
6.75
3 years 1.02
Extreme 1.025
6.75
5 years 1.02
Extreme 1.025
22.91
10 years 1.02
Extreme 1.025
22.91
Change 5d. change 1-year change 3-years change Capi.($)
-1.60%-2.37%+184.62%+107.87% 1.35B
+2.17%+3.02%-0.65%-9.02% 44.74B
+0.39%+0.85%+51.91%+31.44% 34.75B
-0.25%+2.44%+35.64%+37.95% 29.82B
-2.06%-2.47%+7.62%-13.71% 28.37B
-0.55%-2.93%+173.97%+369.82% 19.07B
+3.65%+5.44%+75.36%+232.52% 14.93B
-3.68%+0.63%+65.75%+162.66% 14.32B
-2.46%-8.54%+3,504.15%+3,844.27% 13.93B
+1.06%-0.55%+38.12%+3.42% 13.17B
Average -0.12%-1.17%+413.65%+476.72% 21.45B
Weighted average by Cap. +0.08%-0.67%+270.45%+317.20%

Financials

2026 *2027 *
Net sales 431K 368K 340K 321K 596K 39.8M 609K 4.02M 1.57M 19.2M 1.62M 1.58M 68.56M 127K 109K 101K 94.82K 176K 11.76M 180K 1.19M 463K 5.67M 478K 468K 20.26M
Net income -171M -146M -135M -128M -237M -15.83B -242M -1.6B -623M -7.64B -643M -629M -27.27B -173M -147M -136M -129M -239M -15.94B -244M -1.61B -627M -7.69B -647M -634M -27.46B
Net Debt -173M -148M -137M -129M -239M -15.98B -245M -1.61B -629M -7.71B -649M -635M -27.52B -230M -196M -181M -171M -317M -21.22B -325M -2.14B -835M -10.24B -862M -844M -36.55B
Logo AtaiBeckley Inc.
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
Employees
99
Date Price Change Volume
26-04-09 3.700 $ -1.60% 2,061,789
26-04-08 3.760 $ -0.79% 5,094,431
26-04-07 3.790 $ -1.56% 2,556,076
26-04-06 3.850 $ +1.58% 3,365,456
26-04-02 3.790 $ +2.43% 3,055,073
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
3.700USD
Average target price
13.33USD
Spread / Average Target
+260.36%

Quarterly revenue - Rate of surprise